BG103417A - Condensed pyrimidine bicyclic derivatives - Google Patents

Condensed pyrimidine bicyclic derivatives

Info

Publication number
BG103417A
BG103417A BG103417A BG10341799A BG103417A BG 103417 A BG103417 A BG 103417A BG 103417 A BG103417 A BG 103417A BG 10341799 A BG10341799 A BG 10341799A BG 103417 A BG103417 A BG 103417A
Authority
BG
Bulgaria
Prior art keywords
bicyclic derivatives
condensed pyrimidine
pyrimidine bicyclic
compounds
relates
Prior art date
Application number
BG103417A
Other languages
Bulgarian (bg)
English (en)
Inventor
Lee Arnold
Mikel MOYER
Susan Sobolov-Jaynes
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of BG103417A publication Critical patent/BG103417A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
BG103417A 1996-11-27 1999-05-20 Condensed pyrimidine bicyclic derivatives BG103417A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3186296P 1996-11-27 1996-11-27
US4184697P 1997-04-09 1997-04-09
PCT/IB1997/001393 WO1998023613A1 (en) 1996-11-27 1997-11-05 Fused bicyclic pyrimidine derivatives

Publications (1)

Publication Number Publication Date
BG103417A true BG103417A (en) 2000-06-30

Family

ID=26707706

Family Applications (1)

Application Number Title Priority Date Filing Date
BG103417A BG103417A (en) 1996-11-27 1999-05-20 Condensed pyrimidine bicyclic derivatives

Country Status (24)

Country Link
US (1) US6413971B1 (is)
EP (1) EP0946554A1 (is)
JP (1) JP2000505109A (is)
KR (1) KR20000057228A (is)
CN (1) CN1237177A (is)
AP (1) AP9701146A0 (is)
AR (1) AR010740A1 (is)
AU (1) AU4718997A (is)
BG (1) BG103417A (is)
BR (1) BR9713552A (is)
CA (1) CA2272705C (is)
CO (1) CO4650037A1 (is)
HN (1) HN1997000146A (is)
HR (1) HRP970641A2 (is)
ID (1) ID18958A (is)
IL (1) IL129825A0 (is)
IS (1) IS5041A (is)
MA (1) MA26452A1 (is)
NO (1) NO992524L (is)
OA (1) OA11051A (is)
PA (1) PA8442001A1 (is)
PE (1) PE17299A1 (is)
TN (1) TNSN97192A1 (is)
WO (1) WO1998023613A1 (is)

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1441497A (en) * 1996-01-23 1997-08-20 Novartis Ag Pyrrolopyrimidines and processes for their preparation
DE69720965T2 (de) 1996-02-13 2004-02-05 Astrazeneca Ab Chinazolinderivate und deren verwendung als vegf hemmer
NZ331191A (en) 1996-03-05 2000-03-27 Zeneca Ltd 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
GB9707800D0 (en) 1996-05-06 1997-06-04 Zeneca Ltd Chemical compounds
HRP970371A2 (en) * 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
WO1998013350A1 (en) 1996-09-25 1998-04-02 Zeneca Limited Qinoline derivatives inhibiting the effect of growth factors such as vegf
ZA986729B (en) * 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
ES2289791T3 (es) 1997-08-22 2008-02-01 Astrazeneca Ab Derivados de oxindolilquinazolina como inhibidores de la angiogenesis.
SK286640B6 (sk) * 1998-06-19 2009-03-05 Pfizer Products Inc. Pyrol [2,3-d] pyrimidínová zlúčenina, jej použitie na výrobu liečiva, farmaceutická kompozícia s jej obsahom, použitie jej kombinácie s ďalšími činidlami a súpravy s jej obsahom na výrobu liečiva
PA8474101A1 (es) * 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
UA71945C2 (en) * 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
CA2387351C (en) 1999-10-19 2009-09-08 Merck & Co., Inc. Indole derivatives as tyrosine kinase inhibitors
US6794393B1 (en) 1999-10-19 2004-09-21 Merck & Co., Inc. Tyrosine kinase inhibitors
KR100881105B1 (ko) 1999-11-05 2009-02-02 아스트라제네카 아베 Ｖｅｇｆ 억제제로서의 퀴나졸린 유도체
DE60037345T2 (de) 1999-12-10 2008-11-13 Pfizer Products Inc., Groton Pyrrolo(2,3-d)pyrimidin-Verbindungen
CO5271715A1 (es) 1999-12-21 2003-04-30 Sugen Inc 7-aza-indolin-2-onas sustituidas en 4 y su uso como inhibidores de proteiuna quinasa
US6420382B2 (en) 2000-02-25 2002-07-16 Merck & Co., Inc. Tyrosine kinase inhibitors
US6313138B1 (en) 2000-02-25 2001-11-06 Merck & Co., Inc. Tyrosine kinase inhibitors
ES2267748T3 (es) 2000-04-07 2007-03-16 Astrazeneca Ab Compuestos de quinazolina.
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
BR0111377A (pt) 2000-06-06 2003-06-03 Pfizer Prod Inc Derivados de tiofeno úteis como agentes anticancerìgenos
ATE423120T1 (de) 2000-06-26 2009-03-15 Pfizer Prod Inc Pyrroloä2,3-düpyrimidin verbindungen als immunosuppressive wirkstoffe
ATE303998T1 (de) 2000-10-17 2005-09-15 Merck & Co Inc Oral aktive salze mit tyrosinkinaseaktivität
AU9598601A (en) 2000-10-20 2002-04-29 Eisai Co Ltd Nitrogenous aromatic ring compounds
CN100525768C (zh) 2000-10-23 2009-08-12 史密丝克莱恩比彻姆公司 新化合物
TWI238824B (en) 2001-05-14 2005-09-01 Novartis Ag 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives
US7301023B2 (en) 2001-05-31 2007-11-27 Pfizer Inc. Chiral salt resolution
WO2003000194A2 (en) 2001-06-21 2003-01-03 Pfizer Inc. Thienopyridine and thienopyrimidine anticancer agents
GB0115393D0 (en) * 2001-06-23 2001-08-15 Aventis Pharma Ltd Chemical compounds
US7169788B2 (en) 2001-10-30 2007-01-30 Merck & Co., Inc. Tyrosine kinase inhibitors
HUP0500200A2 (hu) 2002-01-17 2005-07-28 Neurogen Corporation Szubsztituált kinazolin-4-ilamin analógok, mint kapszaicin modulátorok és ezeket tartalmazó gyógyszerkészítmények
AU2003206068A1 (en) 2002-03-01 2003-09-16 Pfizer Inc. Indolyl-urea derivatives of thienopyridines useful as anti-angiogenic agents
UA77303C2 (en) 2002-06-14 2006-11-15 Pfizer Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
NZ539901A (en) 2002-11-26 2007-09-28 Pfizer Prod Inc Method of treatment of transplant rejection
EP1569925A1 (en) * 2002-12-13 2005-09-07 Neurogen Corporation 2-substituted quinazolin-4-ylamine analogues as capsaicin receptor modulators
US7329664B2 (en) * 2003-07-16 2008-02-12 Neurogen Corporation Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues
ES2314444T3 (es) 2003-08-29 2009-03-16 Pfizer Inc. Tienopiridina-fenilacetaminasy sus derivados utiles como nuevos agentes antiangiogenicos.
US20070105865A1 (en) * 2003-09-09 2007-05-10 Neurogen Corporation Substituted bicyclic quinazolin-4-ylamine derivatives
US7683172B2 (en) 2003-11-11 2010-03-23 Eisai R&D Management Co., Ltd. Urea derivative and process for preparing the same
CA2546192C (en) 2003-11-17 2010-04-06 Pfizer Products Inc. Pyrrolopyrimidine compounds useful in treatment of cancer
AU2004309166B2 (en) 2003-12-23 2008-02-21 Pfizer Inc. Novel quinoline derivatives
JP4842929B2 (ja) 2004-05-27 2011-12-21 ファイザー・プロダクツ・インク 癌治療に有用なピロロピリミジン誘導体
CA2569016C (en) * 2004-06-02 2012-11-27 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
ZA200610669B (en) * 2004-06-02 2008-06-25 Takeda Pharmaceutical Fused heterocyclic compound
ATE428421T1 (de) 2004-09-17 2009-05-15 Eisai R&D Man Co Ltd Medizinische zusammensetzung mit verbesserter stabilität und reduzierten gelierungseigenschaften
GB0423554D0 (en) * 2004-10-22 2004-11-24 Cancer Rec Tech Ltd Therapeutic compounds
WO2006091450A1 (en) 2005-02-18 2006-08-31 Lexicon Genetics Incorporated 4-piperidin-1-yl-7h-pyrrolo[2,3-d]pyrimidine compounds
WO2006130673A1 (en) * 2005-05-31 2006-12-07 Janssen Pharmaceutica, N.V. 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders
JP4989476B2 (ja) 2005-08-02 2012-08-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質の効果を検定する方法
TWI392676B (zh) * 2005-12-21 2013-04-11 Abbott Lab 抗病毒化合物、其製備方法及用途
US7910595B2 (en) 2005-12-21 2011-03-22 Abbott Laboratories Anti-viral compounds
WO2007081517A2 (en) 2005-12-21 2007-07-19 Abbott Laboratories Anti-viral compounds
EP2345652A1 (en) 2005-12-21 2011-07-20 Abbott Laboratories Antiviral compounds
RU2441010C2 (ru) * 2005-12-21 2012-01-27 Эбботт Лэборетриз Противовирусные соединения
EP1979349B1 (en) 2005-12-21 2010-07-28 Abbott Laboratories Anti-viral compounds
US7851468B2 (en) * 2006-05-15 2010-12-14 Cephalon, Inc. Substituted pyrazolo[3,4-d]pyrimidines
CN104706637A (zh) 2006-05-18 2015-06-17 卫材R&D管理有限公司 针对甲状腺癌的抗肿瘤剂
WO2008026748A1 (en) 2006-08-28 2008-03-06 Eisai R & D Management Co., Ltd. Antitumor agent for undifferentiated gastric cancer
US20100004238A1 (en) 2006-12-12 2010-01-07 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
US8236950B2 (en) 2006-12-20 2012-08-07 Abbott Laboratories Anti-viral compounds
CA2676796C (en) 2007-01-29 2016-02-23 Eisai R & D Management Co., Ltd. Composition for treatment of undifferentiated gastric cancer
US8952035B2 (en) 2007-11-09 2015-02-10 Eisai R&D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
EA019869B1 (ru) * 2007-11-28 2014-06-30 Дана Фарбер Кансер Инститьют, Инк. Низкомолекулярные миристатные ингибиторы тирозинкиназы bcr-abl и способы их применения
EP2253633A4 (en) 2008-03-12 2012-02-29 Takeda Pharmaceutical CONDENSED HETEROCYCLIC COMPOUND
KR101335843B1 (ko) 2008-08-20 2013-12-02 조에티스 엘엘씨 피롤로[2,3-ｄ]피리미딘 화합물
WO2011018894A1 (en) * 2009-08-10 2011-02-17 Raqualia Pharma Inc. Pyrrolopyrimidine derivatives as potassium channel modulators
MY162940A (en) 2009-08-19 2017-07-31 Eisai R&D Man Co Ltd Quinoline derivative-containing pharmaceutical composition
CN102958523B (zh) 2010-06-25 2014-11-19 卫材R&D管理有限公司 使用具有激酶抑制作用的组合的抗肿瘤剂
WO2012106522A2 (en) * 2011-02-04 2012-08-09 Duquesne University Of The Holy Spirit Bicyclic and tricyclic pyrimidine tyrosine kinase inhibitors with antitubulin activity and methods of treating a patient
CN103402519B (zh) 2011-04-18 2015-11-25 卫材R&D管理有限公司 肿瘤治疗剂
JP6038128B2 (ja) 2011-06-03 2016-12-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
CA2873967A1 (en) 2012-05-21 2013-11-28 Bayer Pharma Aktiengesellschaft Substituted benzothienopyrimidines
EP2867236B1 (en) * 2012-06-29 2017-06-14 Pfizer Inc Novel 4-(substituted-amino)-7h-pyrrolo[2,3-d]pyrimidines as lrrk2 inhibitors
TW201412740A (zh) * 2012-09-20 2014-04-01 Bayer Pharma AG 經取代之吡咯并嘧啶胺基苯并噻唑酮
WO2014048869A1 (en) 2012-09-26 2014-04-03 Bayer Pharma Aktiengesellschaft Substituted indazol-pyrrolopyrimidines useful in the treatment of hyperproliferative diseases
US20150218173A1 (en) 2012-09-26 2015-08-06 Bayer Pharma Aktiengesellschaft Substituted indazol-pyrrolopyrimidines useful in the treatment of hyperfoliferative disorders
NZ706418A (en) 2012-11-29 2019-09-27 Merck Patent Gmbh Azaquinazoline carboxamide derivatives
KR20150098605A (ko) 2012-12-21 2015-08-28 에자이 알앤드디 매니지먼트 가부시키가이샤 퀴놀린 유도체의 비정질 형태 및 그의 제조방법
NZ714049A (en) 2013-05-14 2020-05-29 Eisai R&D Man Co Ltd Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
EP3083618B1 (en) 2013-12-17 2018-02-21 Pfizer Inc Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors
CR20170077A (es) 2014-08-04 2017-06-26 Nuevolution As Derivados de heterociclilo opcionalmente condensados de pirimidina útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias
PT3524595T (pt) 2014-08-28 2022-09-19 Eisai R&D Man Co Ltd Derivado de quinolina altamente puro e método para produção do mesmo
LT3263106T (lt) 2015-02-25 2024-01-10 Eisai R&D Management Co., Ltd. Chinolino darinių kartumo sumažinimo būdas
KR102662228B1 (ko) 2015-03-04 2024-05-02 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
KR102369405B1 (ko) 2015-06-04 2022-03-02 화이자 인코포레이티드 팔보시클립의 고체 투여 형태
MX373231B (es) 2015-06-16 2020-05-08 Eisai R&D Man Co Ltd Agente anticancerigeno.
US12220398B2 (en) 2015-08-20 2025-02-11 Eisai R&D Management Co., Ltd. Tumor therapeutic agent
RU2722149C1 (ru) 2015-09-14 2020-05-27 Пфайзер Инк. Новые производные имидазо[4,5-c] хинолинов и имидазо[4,5-c][1,5] нафтиридинов в качестве ингибиторов LRRK2
GB201520499D0 (en) * 2015-11-20 2016-01-06 Medical Res Council Technology Compounds
PT3497103T (pt) 2016-08-15 2021-06-17 Pfizer Inibidores de piridopirimidinona cdk2/4/6
US12303505B2 (en) 2017-02-08 2025-05-20 Eisai R&D Management Co., Ltd. Tumor-treating pharmaceutical composition
RU2019134940A (ru) 2017-05-16 2021-06-16 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Лечение гепатоцеллюлярной карциномы
WO2020136650A1 (en) 2018-12-25 2020-07-02 Sol-Gel Technologies Ltd. Treatment of skin disorders with compositions comprising an egfr inhibitor
NL2022471B1 (en) 2019-01-29 2020-08-18 Vationpharma B V Solid state forms of oclacitinib
CA3147573A1 (en) 2019-07-17 2021-01-21 2692372 Ontario, Inc. Benzenesulfonamide derivatives and uses thereof
MX2022007265A (es) 2019-12-20 2022-09-09 Nuevolution As Compuestos activos frente a receptores nucleares.
UY38994A (es) 2019-12-20 2021-07-30 Nuevolution As Compuestos activos frente a receptores nucleares
AU2021245397A1 (en) 2020-03-31 2022-10-20 Nuevolution A/S Compounds active towards nuclear receptors
WO2021198956A1 (en) 2020-03-31 2021-10-07 Nuevolution A/S Compounds active towards nuclear receptors
TW202309022A (zh) 2021-04-13 2023-03-01 美商努法倫特公司 用於治療具egfr突變之癌症之胺基取代雜環

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
GB9300059D0 (en) * 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
KR19990067704A (ko) * 1992-12-17 1999-08-25 디. 제이. 우드, 스피겔 알렌 제이 부신피질자극호르몬 유리인자 길항제로서의 피롤로피리미딘을함유하는 약학 조성물
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
RU2137762C1 (ru) * 1994-02-23 1999-09-20 Пфайзер Инк. 4-гетероциклил-замещенные производные хиназолина, фармацевтическая композиция
DE59500788D1 (de) * 1994-05-03 1997-11-20 Ciba Geigy Ag Pyrrolopyrimidinderivate mit antiproliferativer Wirkung
JPH089637A (ja) * 1994-06-20 1996-01-12 Shindengen Electric Mfg Co Ltd Ｆｅｔによる出力スイッチの駆動回路
CA2214086C (en) * 1995-04-03 2008-07-29 Novartis Ag Pyrazole derivatives and processes for the preparation thereof
US5804685A (en) * 1995-06-07 1998-09-08 Neurogen Corporation Deazapurine derivatives: a new class of CRF1 specific ligands
US5644057A (en) * 1995-05-12 1997-07-01 Neurogen Corporation Deazapurine derivatives; a new class of CRF1 specific ligands
JPH08329674A (ja) * 1995-06-02 1996-12-13 Hitachi Ltd 半導体装置
JP3290666B2 (ja) 1995-06-07 2002-06-10 ファイザー・インコーポレーテッド 複素環式の縮合環ピリミジン誘導体
SI9620103A (sl) * 1995-07-06 1998-10-31 Novartis Ag Pirolopirimidini in postopki za njihovo pripravo
PT944629E (pt) * 1996-11-26 2002-12-31 American Cyanamid Co Derivados de biaril-piridoquinazolinona como agentes anti-cancerosos

Also Published As

Publication number Publication date
HN1997000146A (es) 1998-02-26
OA11051A (en) 2003-03-07
JP2000505109A (ja) 2000-04-25
ID18958A (id) 1998-05-28
NO992524D0 (no) 1999-05-26
HRP970641A2 (en) 1998-10-31
CN1237177A (zh) 1999-12-01
AP9701146A0 (en) 1998-01-31
CO4650037A1 (es) 1998-09-03
BR9713552A (pt) 2000-01-25
WO1998023613A1 (en) 1998-06-04
IS5041A (is) 1999-04-30
AR010740A1 (es) 2000-07-12
NO992524L (no) 1999-05-26
US6413971B1 (en) 2002-07-02
EP0946554A1 (en) 1999-10-06
CA2272705C (en) 2003-03-18
IL129825A0 (en) 2000-02-29
TNSN97192A1 (fr) 2005-03-15
CA2272705A1 (en) 1998-06-04
US20020045630A1 (en) 2002-04-18
KR20000057228A (ko) 2000-09-15
AU4718997A (en) 1998-06-22
MA26452A1 (fr) 2004-12-20
PA8442001A1 (es) 2000-05-24
PE17299A1 (es) 1999-02-19

Similar Documents

Publication Publication Date Title
BG103417A (en) Condensed pyrimidine bicyclic derivatives
CA2258548A1 (en) Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases
UA66825C2 (uk) Азаполіциклічні сполуки, конденсовані з арилом, фармацевтична композиція, спосіб лікування та спосіб зниження нікотинової залежності
BG103947A (en) Derivatives of 9-oxymerythromycin
BG103518A (en) 2-(purin-9-yl)tetrahydrofuran-3,4-diol derivatives
AP9901435A0 (en) Bicycle heteroaromatic compounds as protein tyrosine kinase inhibitors.
SE9702001D0 (sv) Novel compounds
MY119181A (en) Aryl pyrimidine derivatives
IL127965A0 (en) Pentafluorobenzenesulfonamide derivatives analogs thereof and pharmaceutical compositions containing the same
HUT71130A (en) Condensed indole derivatives of protein kinase c inhibitor activity, process for preparing them and pharmaceutical compositions containing them
UA39158C2 (uk) Похідні n4-оксикарбоніл-5'-дезокси-5-фторцитидину та фармацевтичний препарат на їх основі
YU11501A (sh) Derivati 4,4,-biarilpiperidina sa aktivnošću na receptor opijata
EP1334719A3 (en) Pentafluorobenzenesulfonamides and analogs
AP9701041A0 (en) Pyridylpyrrole compounds.
MX9702382A (es) Nuevos derivados de pirimidona con actividad antifungica.
GEP20033081B (en) Pharmaceutical Agents for Treatment of Parkinson's Disease, ADFD and Microadenomas
AU1428801A (en) Novel (1,2,3)-triazolo(4,5-D)pyrimidine compounds
AP2001002191A0 (en) 3,3- Biarylpiperine and 2,2-biarylmorpholine derivatives.
YU64400A (sh) Aril fuzirana azapoliciklična jedinjenja
BG103260A (en) The application of 1-hydroxy-2-pyridons for the treatment of seborrheic dermatitis
AU1998995A (en) Substituted fused and bridged bicyclic compounds as therapeutic agents
YU19302A (sh) 4-benzilaminohinolin konjugovan žučnom kiselinom i njegovi heteroanalozi, postupak za njihovu proizvodnju, lekovi koji sadrže ta jedinjenja i njihova primena
YU46302A (sh) Supstituisani piroli
AU579196B2 (en) 4-Oxo-piridol(2,3-d)pyrimidine derivatives, process for their preparation and pharmaceutical compositions containing them
MXPA99003849A (es) Derivados 9a, 11b-deshidro de 9-oxima-3-ceto-6-0-metileritromicina.